Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-05-29

AUTHORS

Katie L. Druce, Laraine Aikman, Maria Dilleen, Annie Burden, Piotr Szczypa, Neil Basu

ABSTRACT

BACKGROUND: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept. METHODS: Two observational studies, comprising RA and AS etanercept commencers, respectively, were analysed. Both provided data on work disability over 1 year and a comprehensive set of putative predictors, including fatigue. A series of repeated measures models were conducted, including baseline variables, visit (6/12 months), and the interaction between visit and each of the explanatory variables. RESULTS: A total of 1003 AS and 1747 RA patients were assessed. For AS, fatigue was significantly associated with presenteeism (linear mixed model coefficient 3.75, 95% confidence interval (CI) 2.14 to 5.36) and activity impairment (2.62, 1.26 to 3.98), but not with work productivity loss (1.81, -0.40 to 4.02) or absenteeism (generalised linear mixed model odds ratio (OR) 1.18, 95% CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient 3.44, 95% CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85), and absenteeism (OR 1.23, 95% CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported a consistent effect of baseline fatigue over time. CONCLUSIONS: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on absenteeism, presenteeism, productivity loss, and activity impairment for RA patients and a significant but dimension-selective effect on work disability among AS patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00544557 . Registered on 16 October 2007. ClinicalTrials.gov, NCT00488475 . Registered on 20 June 2006. More... »

PAGES

96

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-018-1598-8

DOI

http://dx.doi.org/10.1186/s13075-018-1598-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104294056

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29843776


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Absenteeism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disability Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etanercept", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatigue", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Presenteeism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spondylitis, Ankylosing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Work Performance", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Arthritis Research UK Centre for Epidemiology, Faculty of Biology Medicine and Health, the University of Manchester, Manchester, M13 9PT UK", 
          "id": "http://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Arthritis Research UK Centre for Epidemiology, Faculty of Biology Medicine and Health, the University of Manchester, Manchester, M13 9PT UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Druce", 
        "givenName": "Katie L.", 
        "id": "sg:person.0774424113.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774424113.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer, Sandwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Medical Affairs, Pfizer, Sandwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aikman", 
        "givenName": "Laraine", 
        "id": "sg:person.014172437407.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014172437407.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Statistics, Global Product Development, Pfizer, Sandwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Statistics, Global Product Development, Pfizer, Sandwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dilleen", 
        "givenName": "Maria", 
        "id": "sg:person.01264344144.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264344144.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Quanticate, Hitchin, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Quanticate, Hitchin, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burden", 
        "givenName": "Annie", 
        "id": "sg:person.015105144063.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015105144063.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer, Sandwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Medical Affairs, Pfizer, Sandwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Szczypa", 
        "givenName": "Piotr", 
        "id": "sg:person.01136106062.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136106062.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Aberdeen, Aberdeen, UK", 
          "id": "http://www.grid.ac/institutes/grid.7107.1", 
          "name": [
            "Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK", 
            "Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK", 
            "Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Aberdeen, Aberdeen, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Basu", 
        "givenName": "Neil", 
        "id": "sg:person.01000630726.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000630726.71"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10067-007-0642-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029569984", 
          "https://doi.org/10.1007/s10067-007-0642-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar2951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035558632", 
          "https://doi.org/10.1186/ar2951"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-05-29", 
    "datePublishedReg": "2018-05-29", 
    "description": "BACKGROUND: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept.\nMETHODS: Two observational studies, comprising RA and AS etanercept commencers, respectively, were analysed. Both provided data on work disability over 1\u00a0year and a comprehensive set of putative predictors, including fatigue. A series of repeated measures models were conducted, including baseline variables, visit (6/12\u00a0months), and the interaction between visit and each of the explanatory variables.\nRESULTS: A total of 1003 AS and 1747 RA patients were assessed. For AS, fatigue was significantly associated with presenteeism (linear mixed model coefficient 3.75, 95% confidence interval (CI) 2.14 to 5.36) and activity impairment (2.62, 1.26 to 3.98), but not with work productivity loss (1.81, -0.40 to 4.02) or absenteeism (generalised linear mixed model odds ratio (OR) 1.18, 95% CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient 3.44, 95% CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85), and absenteeism (OR 1.23, 95% CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported a consistent effect of baseline fatigue over time.\nCONCLUSIONS: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on absenteeism, presenteeism, productivity loss, and activity impairment for RA patients and a significant but dimension-selective effect on work disability among AS patients.\nTRIAL REGISTRATION: ClinicalTrials.gov, NCT00544557 . Registered on 16 October 2007. ClinicalTrials.gov, NCT00488475 . Registered on 20 June 2006.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13075-018-1598-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "rheumatoid arthritis", 
      "work disability", 
      "activity impairment", 
      "RA patients", 
      "work productivity loss", 
      "productivity loss", 
      "etanercept therapy", 
      "spondylitis patients", 
      "AS patients", 
      "biological therapy", 
      "prevalent symptoms", 
      "baseline variables", 
      "baseline fatigue", 
      "observational study", 
      "patients", 
      "putative predictors", 
      "disability dimensions", 
      "impairment", 
      "independent effects", 
      "etanercept", 
      "arthritis", 
      "disability", 
      "therapy", 
      "presenteeism", 
      "visits", 
      "consistent effect", 
      "significant interaction", 
      "absenteeism", 
      "fatigue", 
      "significant problem", 
      "spondylitis", 
      "symptoms", 
      "total", 
      "loss", 
      "predictors", 
      "effect", 
      "study", 
      "years", 
      "measure model", 
      "variables", 
      "AS", 
      "lack", 
      "hypothesis", 
      "explanatory variables", 
      "data", 
      "time", 
      "series", 
      "interaction", 
      "comprehensive set", 
      "model", 
      "problem", 
      "dimensions", 
      "set", 
      "AS etanercept commencers", 
      "etanercept commencers", 
      "commencers", 
      "dimension-selective effect", 
      "NCT00544557", 
      "NCT00488475", 
      "different work disability dimensions", 
      "work disability dimensions"
    ], 
    "name": "Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients", 
    "pagination": "96", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104294056"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-018-1598-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29843776"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-018-1598-8", 
      "https://app.dimensions.ai/details/publication/pub.1104294056"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_759.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13075-018-1598-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1598-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1598-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1598-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1598-8'


 

This table displays all metadata directly associated to this object as RDF triples.

235 TRIPLES      22 PREDICATES      103 URIs      93 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-018-1598-8 schema:about N0d0fabbc805a4dc3acea9721acc5a0da
2 N136a93db0207419ba4f748b35a3b1796
3 N15af76de436d4ed4a9b3dcf5b818441a
4 N28be515bbcd342dab613d7badb964622
5 N42a25c941e0c484ca919725c68c97970
6 N43f27b18d0a3461daf0f70e0ab8e452f
7 N4fae04267b6b4c58adc3077346363655
8 N69bc43ff29cb4eebaa5c82dbf86b1a80
9 N6a1c555029e6477dac362597bcf41f7a
10 N6e875e7bec954b4bb688376912935028
11 N7ec7c5af38414102888efc2b642b9b0d
12 Nd08a35bb5a68434b8878ac4f251f2e15
13 Nd5ba4b59c0194b7693bf77a701822bc8
14 Nd70cd531b4214cad806b75c7201d51ac
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nc3ca47fe7c4a450dab9670128e4ebde8
18 schema:citation sg:pub.10.1007/s10067-007-0642-x
19 sg:pub.10.1186/ar2951
20 schema:datePublished 2018-05-29
21 schema:datePublishedReg 2018-05-29
22 schema:description BACKGROUND: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept. METHODS: Two observational studies, comprising RA and AS etanercept commencers, respectively, were analysed. Both provided data on work disability over 1 year and a comprehensive set of putative predictors, including fatigue. A series of repeated measures models were conducted, including baseline variables, visit (6/12 months), and the interaction between visit and each of the explanatory variables. RESULTS: A total of 1003 AS and 1747 RA patients were assessed. For AS, fatigue was significantly associated with presenteeism (linear mixed model coefficient 3.75, 95% confidence interval (CI) 2.14 to 5.36) and activity impairment (2.62, 1.26 to 3.98), but not with work productivity loss (1.81, -0.40 to 4.02) or absenteeism (generalised linear mixed model odds ratio (OR) 1.18, 95% CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient 3.44, 95% CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85), and absenteeism (OR 1.23, 95% CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported a consistent effect of baseline fatigue over time. CONCLUSIONS: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on absenteeism, presenteeism, productivity loss, and activity impairment for RA patients and a significant but dimension-selective effect on work disability among AS patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00544557 . Registered on 16 October 2007. ClinicalTrials.gov, NCT00488475 . Registered on 20 June 2006.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N8ca1bdac915b4950b345887937695ce3
27 Ne1afd98d2eb64494a6e403ca67e3a98c
28 sg:journal.1297499
29 schema:keywords AS
30 AS etanercept commencers
31 AS patients
32 NCT00488475
33 NCT00544557
34 RA patients
35 absenteeism
36 activity impairment
37 arthritis
38 baseline fatigue
39 baseline variables
40 biological therapy
41 commencers
42 comprehensive set
43 consistent effect
44 data
45 different work disability dimensions
46 dimension-selective effect
47 dimensions
48 disability
49 disability dimensions
50 effect
51 etanercept
52 etanercept commencers
53 etanercept therapy
54 explanatory variables
55 fatigue
56 hypothesis
57 impairment
58 independent effects
59 interaction
60 lack
61 loss
62 measure model
63 model
64 observational study
65 patients
66 predictors
67 presenteeism
68 prevalent symptoms
69 problem
70 productivity loss
71 putative predictors
72 rheumatoid arthritis
73 series
74 set
75 significant interaction
76 significant problem
77 spondylitis
78 spondylitis patients
79 study
80 symptoms
81 therapy
82 time
83 total
84 variables
85 visits
86 work disability
87 work disability dimensions
88 work productivity loss
89 years
90 schema:name Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients
91 schema:pagination 96
92 schema:productId N03168c0c0f8e430baa27250425b8b20d
93 Ndb215dd4074b439d966a420552c8ecf4
94 Ndefa1aa5fe7e4aab9c53fcb402b38c89
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104294056
96 https://doi.org/10.1186/s13075-018-1598-8
97 schema:sdDatePublished 2021-11-01T18:32
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N6ed548e65a63427e988c4dd838f6ac54
100 schema:url https://doi.org/10.1186/s13075-018-1598-8
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N0264e4d5a1b44b28a72d22aacc1e5cc5 rdf:first sg:person.01136106062.28
105 rdf:rest N2629c4d674bd449482f0eb2b0a158ced
106 N03168c0c0f8e430baa27250425b8b20d schema:name pubmed_id
107 schema:value 29843776
108 rdf:type schema:PropertyValue
109 N0d0fabbc805a4dc3acea9721acc5a0da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Antirheumatic Agents
111 rdf:type schema:DefinedTerm
112 N136a93db0207419ba4f748b35a3b1796 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Spondylitis, Ankylosing
114 rdf:type schema:DefinedTerm
115 N15af76de436d4ed4a9b3dcf5b818441a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N2629c4d674bd449482f0eb2b0a158ced rdf:first sg:person.01000630726.71
119 rdf:rest rdf:nil
120 N28be515bbcd342dab613d7badb964622 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Etanercept
122 rdf:type schema:DefinedTerm
123 N42a25c941e0c484ca919725c68c97970 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Presenteeism
125 rdf:type schema:DefinedTerm
126 N43f27b18d0a3461daf0f70e0ab8e452f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Adult
128 rdf:type schema:DefinedTerm
129 N4fae04267b6b4c58adc3077346363655 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Middle Aged
131 rdf:type schema:DefinedTerm
132 N69bc43ff29cb4eebaa5c82dbf86b1a80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Female
134 rdf:type schema:DefinedTerm
135 N6a1c555029e6477dac362597bcf41f7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Arthritis, Rheumatoid
137 rdf:type schema:DefinedTerm
138 N6e875e7bec954b4bb688376912935028 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Work Performance
140 rdf:type schema:DefinedTerm
141 N6ed548e65a63427e988c4dd838f6ac54 schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N7ec7c5af38414102888efc2b642b9b0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Disability Evaluation
145 rdf:type schema:DefinedTerm
146 N81bcadfbc9d34f88903c897daedd10bb rdf:first sg:person.014172437407.36
147 rdf:rest Ne6c3c00a1bce477c975ba2da4f01e5eb
148 N8ca1bdac915b4950b345887937695ce3 schema:issueNumber 1
149 rdf:type schema:PublicationIssue
150 Nc3ca47fe7c4a450dab9670128e4ebde8 rdf:first sg:person.0774424113.32
151 rdf:rest N81bcadfbc9d34f88903c897daedd10bb
152 Nc9fab592ed8849d3a0e4cae89a5173d6 rdf:first sg:person.015105144063.27
153 rdf:rest N0264e4d5a1b44b28a72d22aacc1e5cc5
154 Nd08a35bb5a68434b8878ac4f251f2e15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Fatigue
156 rdf:type schema:DefinedTerm
157 Nd5ba4b59c0194b7693bf77a701822bc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Absenteeism
159 rdf:type schema:DefinedTerm
160 Nd70cd531b4214cad806b75c7201d51ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Male
162 rdf:type schema:DefinedTerm
163 Ndb215dd4074b439d966a420552c8ecf4 schema:name dimensions_id
164 schema:value pub.1104294056
165 rdf:type schema:PropertyValue
166 Ndefa1aa5fe7e4aab9c53fcb402b38c89 schema:name doi
167 schema:value 10.1186/s13075-018-1598-8
168 rdf:type schema:PropertyValue
169 Ne1afd98d2eb64494a6e403ca67e3a98c schema:volumeNumber 20
170 rdf:type schema:PublicationVolume
171 Ne6c3c00a1bce477c975ba2da4f01e5eb rdf:first sg:person.01264344144.34
172 rdf:rest Nc9fab592ed8849d3a0e4cae89a5173d6
173 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
174 schema:name Medical and Health Sciences
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
177 schema:name Clinical Sciences
178 rdf:type schema:DefinedTerm
179 sg:journal.1297499 schema:issn 1478-6354
180 1478-6362
181 schema:name Arthritis Research & Therapy
182 schema:publisher Springer Nature
183 rdf:type schema:Periodical
184 sg:person.01000630726.71 schema:affiliation grid-institutes:grid.7107.1
185 schema:familyName Basu
186 schema:givenName Neil
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000630726.71
188 rdf:type schema:Person
189 sg:person.01136106062.28 schema:affiliation grid-institutes:grid.418566.8
190 schema:familyName Szczypa
191 schema:givenName Piotr
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136106062.28
193 rdf:type schema:Person
194 sg:person.01264344144.34 schema:affiliation grid-institutes:grid.418566.8
195 schema:familyName Dilleen
196 schema:givenName Maria
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264344144.34
198 rdf:type schema:Person
199 sg:person.014172437407.36 schema:affiliation grid-institutes:grid.418566.8
200 schema:familyName Aikman
201 schema:givenName Laraine
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014172437407.36
203 rdf:type schema:Person
204 sg:person.015105144063.27 schema:affiliation grid-institutes:None
205 schema:familyName Burden
206 schema:givenName Annie
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015105144063.27
208 rdf:type schema:Person
209 sg:person.0774424113.32 schema:affiliation grid-institutes:grid.5379.8
210 schema:familyName Druce
211 schema:givenName Katie L.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774424113.32
213 rdf:type schema:Person
214 sg:pub.10.1007/s10067-007-0642-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1029569984
215 https://doi.org/10.1007/s10067-007-0642-x
216 rdf:type schema:CreativeWork
217 sg:pub.10.1186/ar2951 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035558632
218 https://doi.org/10.1186/ar2951
219 rdf:type schema:CreativeWork
220 grid-institutes:None schema:alternateName Quanticate, Hitchin, UK
221 schema:name Quanticate, Hitchin, UK
222 rdf:type schema:Organization
223 grid-institutes:grid.418566.8 schema:alternateName Medical Affairs, Pfizer, Sandwich, UK
224 Statistics, Global Product Development, Pfizer, Sandwich, UK
225 schema:name Medical Affairs, Pfizer, Sandwich, UK
226 Statistics, Global Product Development, Pfizer, Sandwich, UK
227 rdf:type schema:Organization
228 grid-institutes:grid.5379.8 schema:alternateName Arthritis Research UK Centre for Epidemiology, Faculty of Biology Medicine and Health, the University of Manchester, Manchester, M13 9PT UK
229 schema:name Arthritis Research UK Centre for Epidemiology, Faculty of Biology Medicine and Health, the University of Manchester, Manchester, M13 9PT UK
230 rdf:type schema:Organization
231 grid-institutes:grid.7107.1 schema:alternateName Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Aberdeen, Aberdeen, UK
232 schema:name Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK
233 Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Aberdeen, Aberdeen, UK
234 Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
235 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...